Immediate Impact
6 standout
Citing Papers
Therapeutic strategies for COVID-19: progress and lessons learned
2023 Standout
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
2022 Standout
Works of Sushma Kumar being referenced
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
2019
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Sushma Kumar | 273 | 196 | 93 | 13 | 296 | |
| Randall Tressler | 216 | 233 | 74 | 11 | 319 | |
| J Lange | 189 | 143 | 55 | 17 | 240 | |
| Maddalena Cerrone | 170 | 85 | 107 | 12 | 264 | |
| C Cohen | 247 | 175 | 79 | 18 | 318 | |
| Fiona Bisshop | 250 | 189 | 46 | 17 | 312 | |
| Gràcia Mateo | 138 | 116 | 44 | 16 | 287 | |
| Carlos Fernando de Oliveira | 240 | 196 | 51 | 6 | 261 | |
| Elisabet Deig | 118 | 124 | 57 | 12 | 251 | |
| H.-R. Brodt | 100 | 165 | 124 | 11 | 267 | |
| Suneeta Saghayam | 231 | 131 | 74 | 12 | 302 |
All Works
Loading papers...